{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:59:22Z","timestamp":1785211162836,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chordoma Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Our purpose is to describe the design of a phase II clinical trial on 5-fraction proton therapy for chordomas and chondrosarcomas of the skull base and to present early results in terms of local control and clinical tolerance of the first prospective series. (2) Methods: A dose of 37.5 GyRBE in five fractions was proposed for chordomas and 35 GyRBE in five fractions for chondrosarcomas. The established inclusion criteria are age \u2265 18 years, Karnofsky Performance Status \u2265 70%, clinical target volume up to 50 cc, and compliance with dose restrictions to the critical organs. Pencil beam scanning was used for treatment planning, employing four to six beams. (3) Results: A total of 11 patients (6 chordomas and 5 chondrosarcomas) were included. The median follow-up was 12 months (9\u201315 months) with 100% local control. Acute grade I\u2013II headache (64%), grade I asthenia and alopecia (45%), grade I nausea (27%), and grade I dysphagia (18%) were described. Late toxicity was present in two patients with grade 3 temporal lobe necrosis. (4) Conclusions: Hypofractionated proton therapy is showing encouraging preliminary results. However, to fully assess the efficacy of this therapeutic approach, future trials with adequate sample sizes and extended follow-ups are necessary.<\/jats:p>","DOI":"10.3390\/cancers15235579","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:35:06Z","timestamp":1701056106000},"page":"5579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Five-Fraction Proton Therapy for the Treatment of Skull Base Chordomas and Chondrosarcomas: Early Results of a Prospective Series and Description of a Clinical Trial"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-5675","authenticated-orcid":false,"given":"Morena","family":"Sallabanda","sequence":"first","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-9457","authenticated-orcid":false,"given":"Juan","family":"Vera","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-0202","authenticated-orcid":false,"given":"Ra\u00fal","family":"Matute","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Montero","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"de Pablo","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cerr\u00f3n","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Valero","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Castro","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-8446","authenticated-orcid":false,"given":"Alejandro","family":"Mazal","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[{"name":"Centro de Protonterapia Quironsalud, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s00586-018-5764-0","article-title":"Chordoma: A systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival","volume":"27","author":"Bakker","year":"2018","journal-title":"Eur. Spine J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: Current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jocn.2009.05.003","article-title":"A systematic review of intracranial chondrosarcoma and survival","volume":"16","author":"Bloch","year":"2009","journal-title":"J. Clin. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-013-1172-9","article-title":"Cyberknife radiosurgery for the management of skull base and spinal chondrosarcomas","volume":"114","author":"Jiang","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0360-3016(93)90065-4","article-title":"Probable Causes of recurrence in patients with chordoma and chondrosarcoma of the base of the skull and cervical spine","volume":"25","author":"Austin","year":"1993","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.wneu.2014.07.005","article-title":"Skull base chordoma and chondrosarcoma: Influence of clinical and demographic factors on prognosis: A SEER analysis","volume":"82","author":"Bohman","year":"2014","journal-title":"World Neurosurg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fsurg.2017.00035","article-title":"Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy","volume":"4","author":"Vasudevan","year":"2017","journal-title":"Front. Surg."},{"key":"ref_9","first-page":"e17012","article-title":"Treatment of Chordomas and Chondrosarcomas With CyberKnife Robotic Hypofractionated Radiosurgery: A Single Institution Experience","volume":"13","author":"Sallabanda","year":"2021","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000509386","article-title":"Skull Base Chordomas and Chondrosarcomas","volume":"110","author":"Kremenevski","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000091992","article-title":"Hypofractionated stereotactic radiation therapy for skull base and upper cervical chordoma and chondrosarcoma: Preliminary results","volume":"83","author":"Gwak","year":"2005","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.12688\/f1000research.22440.1","article-title":"Recent advances in understanding and managing chordomas: An update","volume":"9","author":"Connors","year":"2020","journal-title":"F1000Research"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ijrobp.2011.12.047","article-title":"Positron emission tomography\/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: Potential consequences for dose painting","volume":"84","author":"Mammar","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cncr.31958","article-title":"The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base","volume":"125","author":"Palm","year":"2019","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13014-020-01711-3","article-title":"Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy","volume":"15","author":"Basler","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1227\/01.NEU.0000341166.09107.47","article-title":"Treatment of chordomas with CyberKnife: Georgetown University experience and treatment recommendations","volume":"64","author":"Henderson","year":"2009","journal-title":"Neurosurgery"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Riva, G., Cavallo, I., Gandini, S., Ingargiola, R., Pecorilla, M., Imparato, S., Rossi, E., Mirandola, A., Ciocca, M., and Orlandi, E. (2021). Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy. Cancers, 13.","DOI":"10.3390\/cancers13174423"},{"key":"ref_18","unstructured":"(2023, October 13). ClinicalTrials.gov Website, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05861245."},{"key":"ref_19","first-page":"90","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A Story of Hypofractionation and the Table on the Wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2021.08.027","article-title":"Correlation of LET With MRI Changes in Brain and Potential Implications for Normal Tissue Complication Probability for Patients With Meningioma Treated With Pencil Beam Scanning Proton Therapy","volume":"112","author":"Bertolet","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8399","DOI":"10.1088\/0031-9155\/60\/21\/8399","article-title":"A phenomenological relative biological effectiveness (RBE) model for proton therapy based on all published in vitro cell survival data","volume":"60","author":"McNamara","year":"2015","journal-title":"Phys. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nec.2019.12.002","article-title":"Radiation Strategies for Spine Chordoma: Proton Beam, Carbon Ions, and Stereotactic Body Radiation Therapy","volume":"31","author":"Konieczkowski","year":"2020","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.rpor.2016.03.007","article-title":"Review of photon and proton radiotherapy for skull base tumours","volume":"21","author":"Fossati","year":"2016","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ijrobp.2008.12.055","article-title":"Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosacomas of the skull base: First long-term report","volume":"75","author":"Ares","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/153303461000900502","article-title":"The CyberKnife Robotic Radiosurgery System in 2010","volume":"9","author":"Kilby","year":"2010","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1179\/174313208X297878","article-title":"Gamma knife radiosurgery for residual skull base chordomas","volume":"30","author":"Liu","year":"2008","journal-title":"Neurol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1227\/NEU.0b013e3181ffa12c","article-title":"Stereotactic radiosurgery for chordoma: A report from the North American Gamma Knife Consortium","volume":"68","author":"Kano","year":"2011","journal-title":"Neurosurgery"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-012-0858-8","article-title":"Stereotactic radiosurgery for intracranial chondrosarcoma","volume":"108","author":"Iyer","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3171\/2014.12.JNS132580","article-title":"Skull base chondrosarcoma radiosurgery: Report of the North American Gamma Knife Consortium","volume":"123","author":"Kano","year":"2015","journal-title":"J. Neurosurg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1227\/NEU.0000000000000083","article-title":"Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum","volume":"73","author":"Yamada","year":"2013","journal-title":"Neurosurgery"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jocn.2012.01.005","article-title":"Management of intracranial and extracranial chordomas with CyberKnife stereotactic radiosurgery","volume":"19","author":"Jiang","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clon.2022.02.009","article-title":"How Low Can You Go? The Radiobiology of Hypofractionation","volume":"34","author":"Brand","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13566-019-00398-8","article-title":"Assessment of the alpha\/beta ratio of the optic pathway to adjust hypofractionated stereotactic radiosurgery regimens for perioptic lesions","volume":"8","author":"Speckter","year":"2019","journal-title":"J. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/10929088.2011.565160","article-title":"Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors","volume":"16","author":"Mahadevan","year":"2011","journal-title":"Comput. Aided Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2014.10.011","article-title":"Dose\u2013volume relationships associated with temporal lobe radiation necrosis after skull base proton beam therapy","volume":"91","author":"McDonald","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_39","unstructured":"(2023, October 11). PTCOG Website. Available online: https:\/\/www.ptcog.site\/index.php\/facilities-in-operation-public."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Santos, A., Penfold, S., Gorayski, P., and Le, H. (2022). The Role of Hypofractionation in Proton Therapy. Cancers, 14.","DOI":"10.3390\/cancers14092271"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3171\/2018.12.JNS181578","article-title":"Dosimetric comparisons of different hypofractionated stereotactic radiotherapy techniques in treating intracranial tumors > 3 cm in longest diameter","volume":"132","author":"Cao","year":"2020","journal-title":"J. Neurosurg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20190291","DOI":"10.1259\/bjr.20190291","article-title":"Proton RBE Dependence on Dose in the Setting of Hypofractionation","volume":"93","author":"Friedrich","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Paganetti, H. (2014). Relative Biological Effectiveness (RBE) Values for Proton Beam Therapy. Variations as a Function of Biological Endpoint, Dose, and Linear Energy Transfer. Phys. Med. Biol., 59.","DOI":"10.1088\/0031-9155\/59\/22\/R419"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sgalambro, F., Zugaro, L., Bruno, F., Palumbo, P., Salducca, N., Zoccali, C., Barile, A., Masciocchi, C., and Arrigoni, F. (2022). Interventional Radiology in the Management of Metastases and Bone Tumors. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123265"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mercatali, L., Vanni, S., Miserocchi, G., Liverani, C., Spadazzi, C., Cocchi, C., Calabrese, C., Gurrieri, L., Fausti, V., and Riva, N. (2022). The emerging role of cancer nanotechnology in the panorama of sarcoma. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.953555"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Traylor, J.I., Pernik, M.N., Plitt, A.R., Lim, M., and Garzon-Muvdi, T. (2021). Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence. Cancers, 13.","DOI":"10.3390\/cancers13102408"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:30:02Z","timestamp":1760131802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":46,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235579"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235579","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]}}}